tbuckley/cabot-search huggingface dataset:
A phase II study of cetuximab-based neoadjuvant and adjuvant treatment strategies, with or without surgery, in patients with locally very advanced squamous cell carcinoma of the oral cavity.
Authors: Pei-Jen Lou, Chun-Ta Liao, Cheng-Ping Wang, Shiang-Fu Huang, Shin-June Cheng, Cheng-Lung Hsu, Chun-Wei Wang, Tung-Chieh Chang, Ya-Fang Chen, Chien-Yu Lin, Hung-Ming Wang, Ruey-Long Hong
Journal: Journal of Clinical Oncology (2012)

e16050 Background: The purpose is to evaluate the efficacy of sequential regimen using cetuximab-based doublet neoadjuvant chemotherapy, followed by surgery, if tumors resectable, and adjuvant cetuximab-based chemoradiotherapy in locally very advanced OSCC patients. Methods: Patients with T4a/b or N2b/c or N3 OSCC were enrolled to determine the response rate of cetuximab, cisplatin, and 5-FU neo-adjuvant chemotherapy. Cetuximab (400 mg/m 2 loading, followed by 250 mg/m 2 weekly x 6 weeks) was combined with 2 3-weekly cycles of cisplatin (100 mg/m 2 ) and 5-FU (1000 mg/m 2 x 3 days) as neo-adjuvant. Patients whose tumors became operable after neoadjuvant underwent radical surgery followed by adjuvant weekly cetuximab (250 mg/m 2 ), cisplatin (30 mg/m 2 ) and XRT (up to 70 Gy). Patients whose tumors remained inoperable after neoadjuvant received weekly cetuximab (250 mg/m 2 ), cisplatin (30 mg/m 2 ) and XRT (up to 70 Gy). Results: 33 patients were enrolled from Dec. 2009 to Jan. 2011. Average age was 47.3 years. 51.5% had primary lesion in buccal mucosa and 21.2% on tongue. 66.7% and 27.2% had T4b or T4a disease respectively, while 72.7% had N2b/N2c/N3 disease. 28/33 completed treatment course. On ITT analysis, 39.4% (13/33) had partial response and 48.5% (16/33) had stable disease after neoadjuvant. 42.4% (14/33) underwent radical surgery after neoadjuvant, while another 9% (3/33) underwent surgery after bio-chemoradiation. The 1 year disease free survival (resected group), progression free survival (ITT group), and overall survival (ITT group) were 48.8%, 73.2%, and 51.7% respectively. The most common grade 3/ 4 adverse event in neo-adjuvant phase was vomiting (16.1%), while mucositis (75%) and dermatitis (42.8%) accounted for major grade 3/ 4 adverse events during bio-chemoradiation. Conclusions: Cetuximab based sequential regimen was efficacious and well tolerated in improving treatment outcomes in locally very advanced OSCC patients with manageable side effects.
All-Trans-Retinoic Acid (ATRA) Combined with Lithium As Treatment of Relapsed Non-Progranulocytic AML: Therapeutic Targeting Inhibition of the Glycogen Synthase Kinase 3-Beta (GSK3) Enzyme
Authors: Paolo Caimi, Kalpana Gupta, Tammy Stefan, Brenda Cooper, Basem M. William, Erica L Campagnaro, Richard J. Creger, Donna Kane, Stanton L. Gerson, Hillard M. Lazarus, Marcos de Lima, David N. Wald
Journal: Blood (2014)
Salvage Therapy with Flag/Idarubicin/Mylotarg (Flag-IM) Results in a Superior CR/CRp Rate and Low Toxicity When Compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in Patients with Relapsed and Refractory AML.
Authors: Brian A. Van Tine, Kristan M. Augustin, David I. Kuperman, Bruno Nervi, Peter Westervelt, John F. DiPersio
Journal: Blood (2006)
Abstract P2-01-13: Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?
Authors: MHR Chowdhury, K Thillai, A Lucey, V Michalarea, A Mera, E Karapanagiotou, I Sandri, J Mansi
Journal: Cancer Research (2017)

Abstract Background For patients who receive primary chemotherapy for their early breast cancer the current practice for lymph node positive (LN) disease at presentation is in transition, with a drive towards sentinel LN biopsy (SLNB) rather than axillary node clearance (ANC) for patients who achieve a good response to primary chemotherapy. Boileau et al initially reported that approximately 30% of patients could potentially avoid clearance, but with a recommendation for further evaluation before including SLNB in guidelines for biopsy proven node-positive disease prior to primary chemotherapy for early breast cancer. Methods This was a retrospective single centre study. Examining the records of all patients who had received primary chemotherapy between January 2010 and October 2014. Patients were identified through the Guy's Breast Cancer Database and chemotherapy prescribing system. To fully assess the LN status, all patients were cross-referenced with the electronic notes on our electronic noting system (MOSAIQ), radiology on Patient Archiving and Communication System (PACS) and histology on our Electronic Patient Record (EPR). Results: 1526 patients were identified, of whom 156 underwent primary chemotherapy. 111 patients had suspicious nodes on imaging (ultrasound and/or MRI) and underwent LN biopsy. 69 patients had positive nodes pre-chemotherapy. 28 of these 69 patients (40.6%) had negative nodes at ANC, of these 14 (50%) had complete pathological complete response (pCR) in their primary tumour(s) of whom 12 (86%) had radiological CR prior to surgery. Of the 41 who remained positive only three achieved pCR of their primary tumour after chemotherapy. 22 patients were LN positive post primary chemotherapy, despite having been identified as initially LN negative. Of these 9 had a negative pre chemotherapy biopsy, and only 1 of these 22 patients had a pCR. Discussion: We have confirmed that ANC may be avoided in selected patients with LN involvement at presentation. In our series over 40% could have had SLNB instead. Factors supporting this approach include those patients who have an excellent radiological response to primary chemotherapy. Conversely, 22 of 87 (25%) had positive LN after chemotherapy having been initially thought to be LN negative at presentation, highlighting the possible need for multiple nodal sampling prior to chemotherapy as well as further nodal assessment after chemotherapy for complete staging. Citation Format: Chowdhury MHR, Thillai K, Lucey A, Michalarea V, Mera A, Karapanagiotou E, Sandri I, Mansi J. Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-13.
Quantitative Expression Analysis of WT1 Main Isoforms in AML
Authors: Irene Luna, Esperanza Such, Jose Cervera, Eva Barragan, Marta Llop, Mariam Ibañez, Inés Gómez-Seguí, Beatriz Costan, Oscar Fuster, Sandra Dolz, Federico Moscardo, Pau Montesinos, Maria López-Pavia, David Martinez-Cuadrón, Silvestre Oltra, Pascual Bolufer, Miguel A. Sanz
Journal: Blood (2011)
Infusion of DDAVP Does Not Improve Primary Hemostasis in Patients with Cirrhosis
Authors: Freeha Arshad, Sara C.M. Stoof, Frank W.G. Leebeek, Karin Ruitenbeek, Jelle Adelmeijer, Hans Blokzijl, Arie P. van den Berg, Robert J. Porte, Marieke J.H.A. Kruip, Ton Lisman
Journal: Blood (2014)
Gene expression profiling and copy number analysis to identify predictive molecular markers in breast cancer: Successful use of formalin fixed paraffin embedded tissue (FFPE)
Authors: M. Y. Iddawela, Y. Wang, R. Russell, G. Cowley, M. El-Sheemy, J. Eremin, O. Eremin, M. Faham, H. M. Earl, C. Caldas
Journal: Journal of Clinical Oncology (2009)

574 Background: FFPE is a valuable and widely available resource for translational research which to date has been under-used due to technical limitations. Improvement in technology has enabled genome-wide analysis of FFPE samples. We have assessed gene expression and copy number changes in the same cohort of breast cancers to identify markers or pathways important in prediction of treatment response. Methods: FFPE tissues from patients treated with neoadjuvant adriamycin/cyclophosphamide followed by taxanes in a clinical study were used. Gene expression profiling was assessed using the cDNA mediated annealing selection and ligation assay using the cancer panel which assess 502 genes (DASL assay, Illumina). Data was analysed using BeadStudio software. Copy number changes were assessed using the Molecular inversion probe assay with the 50K SNP panel (Affymetrix, California) and analysed using Nexus software (Biodiscovery). Results: Gene expression profiling was carried out on 44 samples. 12/44 (27%) patients had a pathological complete response (pCR) following chemotherapy. Significant differential expression of genes between pCR and non-pCR cancers were shown. TNFRSF5, CTSD, BCL3, ARNT, BIRC3, TGFBR1, MLLT6, and EVI2A were over-expressed and COL18A1, FGF12, IGFBP1 and NOTCH4 which were down-regulated in cancers that have a pCR (p ≤ 0.01). Copy number changes were assessed in 33 samples and comparison of copy number changes in pCR vs. non-pCR showed gains in regions 6q22, 21q21, 4p14, 4q21, 4p14, and loss at 11q11 (p ≤ 0.01). Three regions containing microRNA coding sequences, mir130a (11q11) mir142 (17q23) and mir21 (17q23) showed significant loss among pCR tumours (p &lt; 0.05). Conclusions: This feasibility study shows that FFPE can be used for gene expression and copy number analysis which is a useful tool for the discovery of predictive markers for treatment response in neoadjuvant treatment trials. The role of TNFRSF5, microRNA 21/130a/142, and 11q11 loss should be further investigated as predictive markers of response to chemotherapy. [Table: see text]
Variation in the Small Guanosine Triphosphate (GTP)-Binding Protein, Secretion-Associated and RAS-Related (SAR1A) Gene and Response to Hydroxyurea Treatment in Sickle Cell Disease.
Authors: Chutima Kumkhaek, Jianqiong Zhu, James G. Taylor, Carolyn Hoppe, Gregory J. Kato, Griffin P. Rodgers
Journal: Blood (2007)
Time-Related Microcirculatory Dysfunction in Patients With Takotsubo Cardiomyopathy
Authors: Fernando Rivero, Javier Cuesta, Marcos García-Guimaraes, Teresa Bastante, Teresa Alvarado, Paula Antuña, Fernando Alfonso
Journal: JAMA Cardiology (2017)

Time-Related Microcirculatory Dysfunction in Patients With Takotsubo CardiomyopathyTakotsubo cardiomyopathy (TCM) has been described as an acute reversible heart failure syndrome resulting from a transient contractile dysfunction of a large region of the left ventricular myocardium in the absence of epicardial coronary obstruction or plaque rupture. 1 In these patients, acute microvascular impairment has been previously demonstrated at the time of clinical presentation by measuring the index of microvascular resistance (IMR). 2 In the present study, we sought to prospectively assess the presence of microcirculatory dysfunction by invasively measuring the IMR in patients presenting with TCM.Specifically, we sought to elucidate whether a time-dependent trend in microvascular damage resolution exists.
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.
Authors: Rudiger Hehlmann, Susanne Jung-Munkwitz, Michael Lauseker, Armin Leitner, Nadine Pletsch, Samina Shazi, Martin C. Müller, Claudia Haferlach, Brigitte Schlegelberger, Susanne Schnittger, Cornelius F. Waller, Andreas Neubauer, Lothar Kanz, Mathias Hänel, Jiri Mayer, Frank Stegelmann, Roland Fuchs, Wolfgang E. Berdel, Leopold Balleisen, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans- Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Joerg Hasford, Andreas Hochhaus, Susanne Saussele
Journal: Blood (2009)
Eradicating a Genetic Mutation
Authors: Maryl Goldberg Sackeim
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anatomy of the Brain. A Text-Book for Medical Students.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do patients with obstructive sleep apnoea deserve new dedicated antihypertensive strategies?
Authors: Renaud Tamisier, Patrick Lévy, Jean-Louis Pépin
Journal: Thorax (2017)

Hypertension affects 25% of the adult population and remains a leading cause of cardiovascular mortality, accounting for 13.5% of all deaths. Half of all strokes and ischaemic heart disease events are attributed to hypertension.1 ,2 Most patients exhibit grade I hypertension (systolic blood pressure of 140–159 mm Hg and/or diastolic blood pressure of 90–99 mm Hg) without coexisting cardiovascular disease. Effective reduction of blood pressure in this population significantly reduces stroke and death.3

Obstructive sleep apnoea (OSA) is now recognised as a risk factor for the development of hypertension in European and the US International Guidelines. In OSA, elevation of blood pressure is in part due to intermittent hypoxaemia leading to increased sympathetic tone and impaired baroreflex gain.4 Altered arterial vasoconstriction and vasodilatation5 owing to stimulation of the renin-angiotensin-aldosterone system (RAAS)6 are also significant contributors. Although OSA and hypertension are tightly linked in a dose-response manner, the impact of short-term OSA treatment on blood pressure reduction in unselected patient populations with OSA is rather mild, about 2 mm Hg reduction in 24-hour mean blood pressure. This effect is slightly greater in patients who are compliant with CPAP or mandibular advancement devices, presumably by allowing rapid eye movement (REM) sleep at the end of the night to be free of obstructive respiratory events.7–9

It stands to reason that treatment strategies combining OSA treatment and pharmacological antihypertensives would be synergistic.10 ,11 Previous studies10 ,11 have demonstrated that in hypertensive patients with OSA, losartan or valsartan are by far more effective than CPAP in reducing blood pressure, even if nocturnal blood pressure is better controlled when CPAP is used concurrently with these medications. This underlines the need for specific strategies to be further studied in …
CNS Disease In Younger Patients (&lt;=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)
Authors: Norbert Schmitz, Samira Zeynalova, Bertram Glass, Ulrich Kaiser, Eva Cavallin-Stahl, Max Wolf, Mathias Haenel, Markus Loeffler, Lorenz Trümper, M. Pfreundschuh
Journal: Blood (2010)
Phosphoproteomic Analysis of Primary Acute Myeloid Leukemia Cells Reveals Redundant Roles for Src Family Kinases in AML Survival
Authors: Jamil K. Dierov, Tae Kon Kim, Xiaowei Yang, Alexander Perl, Beth A Burke, Zhu Wang, Ting-Lei Gu, Alan M. Gewirtz, Seth J. Corey, Roberto Polakiewicz, Martin Carroll
Journal: Blood (2008)
Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline
Authors: Larissa Nekhlyudov, Christina Lacchetti, Nancy B. Davis, Thomas Q. Garvey, David P. Goldstein, J. Chris Nunnink, Jose I. Ruades Ninfea, Andrew L. Salner, Talya Salz, Lillian L. Siu
Journal: Journal of Clinical Oncology (2017)

Purpose This guideline provides recommendations on the management of adults after head and neck cancer (HNC) treatment, focusing on surveillance and screening for recurrence or second primary cancers, assessment and management of long-term and late effects, health promotion, care coordination, and practice implications. Methods ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. The American Cancer Society (ACS) HNC Survivorship Care Guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel reviewed the content and recommendations, offering modifications and/or qualifying statements when deemed necessary. Results The ASCO Expert Panel determined that the ACS HNC Survivorship Care Guideline, published in 2016, is clear, thorough, clinically practical, and helpful, despite the limited availability of high-quality evidence to support many of the recommendations. ASCO endorsed the ACS HNC Survivorship Care Guideline, adding qualifying statements aimed at promoting team-based, multispecialty, multidisciplinary, collaborative head and neck survivorship care. Recommendations The ASCO Expert Panel emphasized that caring for HNC survivors requires a team-based approach that includes primary care clinicians, oncology specialists, otolaryngologists, dentists, and other allied professionals. The HNC treatment team should educate the primary care clinicians and patients about the type(s) of treatment received, the likelihood of potential recurrence, and the potential late and long-term complications. Primary care clinicians should recognize symptoms of recurrence and coordinate a prompt evaluation. They should also be prepared to manage late effects either directly or by referral to appropriate specialists. Health promotion is critical, particularly regarding tobacco cessation and dental care. Additional information is available at www.asco.org/HNC-Survivorship-endorsement and www.asco.org/guidelineswiki .
Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.
Authors: Steffen Klippel, Jana Jakubikova, Jake Delmore, Melissa G. Ooi, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2009)
Scanometry as microplate reader for high throughput method based on DPPH dry reagent for antioxidant assay
Authors: Mochammad Amrun Hidayat, Aulia Fitri, Bambang Kuswandi
Journal: Acta Pharmaceutica Sinica B (2017)

The stable chromogenic radical 1,1'-diphenyl-2-picrylhydrazyl (DPPH) solution was immobilized on the microwell plate as dry reagent to construct a simple antioxidant sensor. Then, a regular flatbed scanner was used as microplate reader to obtain analytical parameters for antioxidant assay using one-shot optical sensors as scanometry technique. Variables affecting the acquisition of the images were optimized and the analytical parameters are obtained from an area of the sensing zone inside microwell using the average luminosity of the sensing zone captured as the mean of red, green, and blue (RGB) value using ImageJ® program. By using this RGB value as sensor response, it is possible to determine antioxidant capacity in the range 1-25 ppm as gallic acid equivalent (GAE) with the response time of 9 min. The reproducibility of sensor was good (RSD<1%) with recovery at 93%-96%. The antioxidant sensor was applied to the plant extracts, such as sappan wood and Turmeric Rhizome. The results are good when compared to the same procedure using a UV/Vis spectrophotometer.
Neutrophil Transmigration into the Joint of RA-Induced Mouse Is Markedly Blocked By EC-18, Via STAT3 Signaling
Authors: Jae Min Shin, Young-Jun Kim, Sun Young Yoon, Myung-Hwan Kim, Cheolwon Suh, Ki-Young Sohn, Heung-Jae Kim, Yong-Hae Han, Saeho Chong, Jae Wha Kim
Journal: Blood (2015)
Saquinavir Inhibits Proliferation and Promotes Apoptosis in Imatinib-Resistant Chronic Myelogenous Leukemia Lines and Inhibits CFU-GM Growth in CML Blastic Crisis.
Authors: Fabio S. Timeus, Nicoletta Crescenzio, Alessandra Doria, Luiselda C. Foglia, Daniele Bertin, Giuseppe Saglio, Pier Angelo Tovo
Journal: Blood (2005)